EUCTR2013-004282-14-HU进行中（未招募）1 期
PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS - GARDENIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 18-80 years of age, inclusive.
- •- Diagnosis of UC established at least 3 months prior to Day 1 by clinical and endoscopic evidence
- •- Moderately to severely active UC as determined by the Mayo Clinic Score assessment (MCS)
- •- Evidence of UC extending a minimum of 20 cm from the anal verge as determined by baseline endoscopy
- •- Naive to treatment with any anti-TNF inhibitor therapy
- •- An inadequate response to, loss of response to, or intolerance to prior corticosteroid and/or immunosuppressant treatment
- •- Background regimen for UC may include oral 5-aminosalicylic acid (5-ASA), oral corticosteroids, budenoside, probiotics, azathioprine (AZA), 6-mercaptopurine(6-MP), or methotrexate (MTX) if doses are stable, as defined by the protocol
- •- Use of highly effective contraception as defined by the protocol
- •- Received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 370
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- •- A history of or current conditions and diseases affecting the digestive tract, such as ileostomy or colostomy indeterminate colitis, suspicion of ischemic colitis, radiation colitis, or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous
- •colonic polyps
- •- Have received non-permitted inflammatory bowel disease (IBD) therapies (including etrolizumab or other anti-integrin agents such as natalizumab, vedolizumab, and efalizumab), as stated in the protocol
- •- Any prior treatment with anti-adhesion molecules (e.g., anti-MAdCAM-1)
- •- Any prior treatment with rituximab
- •- Any treatment with tofacitinib during screening
- •- History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to etrolizumab or any of the excipients
- •- Neurologic conditions or diseases that may interfere with monitoring for PML
- •- History of demyelinating disease
- •- Clinically significant abnormalities on screening neurologic examination (PML Objective/Subjective Checklists)
- •- History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, within 5 years before screening, as defined by the protocol
- •- Congenital or acquired immune deficiency, chronic hepatitis B or C infection, HIV positive or history of tuberculosis (active or latent)
- •- Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin testing) within 60 days prior to Day 1 or other intestinal pathogens within 30 days prior to Day 1.
- •- Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis within 60 days prior to Day 1.
- •- History of recurrent opportunistic infections and/or history of severe disseminated viral infections, or organ transplant
- •- Any serious opportunistic infection within the last 6 months
- •- Any major episode of infection requiring treatment with IV antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
- •- Received a live attenuated vaccine within 4 weeks prior to Day 1
研究者
相似试验
进行中（未招募）
1 期
A study of the effectiveness (efficacy) and safety of etrolizumab compared with infliximab in ulcerative colitis patients who have not previously received TNF inhibitorslcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-004282-14-NLF. Hoffmann-La Roche Ltd720
进行中（未招募）
不适用
A study of the effectiveness (efficacy) and safety of etrolizumab compared with infliximab in ulcerative colitis patients who have not previously received TNF inhibitorslcerative ColitisMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-004282-14-ITF. Hoffmann-La Roche Ltd720
进行中（未招募）
1 期
A study to evaluate the effectiveness (efficacy) and safety of etrolizumab compared with infliximab in patients with moderate to severe ulcerativecolitis who have not previously received TNF inhibitorslcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-004282-14-PTF. Hoffmann-La Roche Ltd397
已完成
3 期
PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORSUlcerative colitisNL-OMON47727Hoffmann-La Roche14
进行中（未招募）
1 期
A study to evaluate the effectiveness (efficacy) and safety of etrolizumab compared with infliximab in patients with moderate to severe ulcerative colitis who have not previously received TNF inhibitorslcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-004282-14-CZF. Hoffmann-La Roche Ltd390